UCB SA (UCB.BR)
EUR 187.45
(0.83%)
EUR 187.45
(0.83%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 15.53 Billion EUR | -2.07% |
| 2022 | 15.86 Billion EUR | 11.67% |
| 2021 | 14.21 Billion EUR | 6.69% |
| 2020 | 13.31 Billion EUR | 20.2% |
| 2019 | 11.08 Billion EUR | 5.39% |
| 2018 | 10.51 Billion EUR | 6.02% |
| 2017 | 9.91 Billion EUR | -2.89% |
| 2016 | 10.21 Billion EUR | -6.79% |
| 2015 | 10.95 Billion EUR | 7.96% |
| 2014 | 10.14 Billion EUR | 3.98% |
| 2013 | 9.76 Billion EUR | 4.27% |
| 2012 | 9.36 Billion EUR | 1.98% |
| 2011 | 9.17 Billion EUR | 2.33% |
| 2010 | 8.96 Billion EUR | -1.66% |
| 2009 | 9.12 Billion EUR | -4.24% |
| 2008 | 9.52 Billion EUR | -0.32% |
| 2007 | 9.55 Billion EUR | -8.98% |
| 2006 | 10.49 Billion EUR | 122.56% |
| 2005 | 4.71 Billion EUR | -12.22% |
| 2004 | 5.37 Billion EUR | 73.85% |
| 2003 | 3.09 Billion EUR | 17.93% |
| 2002 | 2.62 Billion EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 15.62 Billion EUR | 0.0% |
| 2023 FY | 15.53 Billion EUR | -2.07% |
| 2023 Q2 | 15.38 Billion EUR | 0.0% |
| 2023 Q4 | 15.53 Billion EUR | 0.0% |
| 2022 FY | 15.86 Billion EUR | 11.67% |
| 2022 Q2 | 16.3 Billion EUR | 0.0% |
| 2022 Q4 | 15.86 Billion EUR | 0.0% |
| 2021 Q2 | 13.03 Billion EUR | 0.0% |
| 2021 Q4 | 14.21 Billion EUR | 0.0% |
| 2021 FY | 14.21 Billion EUR | 6.69% |
| 2020 Q4 | 13.31 Billion EUR | 0.0% |
| 2020 Q2 | 13.21 Billion EUR | 0.0% |
| 2020 FY | 13.31 Billion EUR | 20.2% |
| 2019 Q4 | 11.08 Billion EUR | 0.0% |
| 2019 FY | 11.08 Billion EUR | 5.39% |
| 2019 Q2 | 10.51 Billion EUR | 0.0% |
| 2018 Q4 | 10.51 Billion EUR | 0.0% |
| 2018 FY | 10.51 Billion EUR | 6.02% |
| 2018 Q2 | 10.19 Billion EUR | 0.0% |
| 2017 FY | 9.91 Billion EUR | -2.89% |
| 2017 Q2 | 9.8 Billion EUR | 0.0% |
| 2017 Q4 | 9.91 Billion EUR | 0.0% |
| 2016 Q4 | 10.21 Billion EUR | 0.0% |
| 2016 FY | 10.21 Billion EUR | -6.79% |
| 2016 Q2 | 10.19 Billion EUR | 0.0% |
| 2015 Q4 | 10.95 Billion EUR | 0.0% |
| 2015 Q2 | 10.55 Billion EUR | 0.0% |
| 2015 FY | 10.95 Billion EUR | 7.96% |
| 2014 Q2 | 9.72 Billion EUR | 0.0% |
| 2014 FY | 10.14 Billion EUR | 3.98% |
| 2014 Q4 | 10.14 Billion EUR | 0.0% |
| 2013 Q4 | 9.9 Billion EUR | 0.0% |
| 2013 FY | 9.76 Billion EUR | 4.27% |
| 2013 Q2 | 9.55 Billion EUR | 0.0% |
| 2012 Q2 | 9.37 Billion EUR | 0.0% |
| 2012 FY | 9.36 Billion EUR | 1.98% |
| 2012 Q4 | 9.36 Billion EUR | 0.0% |
| 2011 Q4 | 9.17 Billion EUR | 0.0% |
| 2011 Q2 | 8.5 Billion EUR | 0.0% |
| 2011 FY | 9.17 Billion EUR | 2.33% |
| 2010 FY | 8.96 Billion EUR | -1.66% |
| 2010 Q4 | 8.96 Billion EUR | 0.0% |
| 2010 Q2 | 9.96 Billion EUR | 0.0% |
| 2009 Q4 | 9.12 Billion EUR | 0.0% |
| 2009 FY | 9.12 Billion EUR | -4.24% |
| 2008 FY | 9.52 Billion EUR | -0.32% |
| 2007 FY | 9.55 Billion EUR | -8.98% |
| 2006 FY | 10.49 Billion EUR | 122.56% |
| 2005 FY | 4.71 Billion EUR | -12.22% |
| 2004 FY | 5.37 Billion EUR | 73.85% |
| 2003 FY | 3.09 Billion EUR | 17.93% |
| 2002 FY | 2.62 Billion EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ABIONYX Pharma SA | 14.71 Million EUR | -105535.622% |
| ABIVAX Société Anonyme | 327.06 Million EUR | -4651.087% |
| Adocia SA | 24.95 Million EUR | -62165.587% |
| Aelis Farma SA | 26.28 Million EUR | -59026.365% |
| Biophytis S.A. | 11.93 Million EUR | -130085.992% |
| Advicenne S.A. | 12.4 Million EUR | -125143.814% |
| genOway Société anonyme | 31.84 Million EUR | -48699.76% |
| IntegraGen SA | 8 Million EUR | -194128.978% |
| Medesis Pharma S.A. | 1.92 Million EUR | -806561.354% |
| Neovacs S.A. | 47.53 Million EUR | -32590.563% |
| NFL Biosciences SA | 3.97 Million EUR | -391248.673% |
| Plant Advanced Technologies SA | 14.91 Million EUR | -104098.204% |
| Quantum Genomics Société Anonyme | 3.74 Million EUR | -414630.444% |
| Sensorion SA | 46.49 Million EUR | -33321.461% |
| Theranexus Société Anonyme | 7.23 Million EUR | -214594.179% |
| TME Pharma N.V. | 2.49 Million EUR | -623705.701% |
| Valbiotis SA | 33.24 Million EUR | -46636.647% |
| TheraVet SA | 7.53 Million EUR | -206146.458% |
| Valerio Therapeutics Société anonyme | 35.27 Million EUR | -43952.276% |
| argenx SE | 4.11 Billion EUR | -277.883% |
| BioSenic S.A. | 9.55 Million EUR | -162458.845% |
| Celyad Oncology SA | 16.28 Million EUR | -95336.679% |
| DBV Technologies S.A. | 165.65 Million USD | -9280.585% |
| Galapagos NV | 4.35 Billion EUR | -256.612% |
| Genfit S.A. | 173.87 Million EUR | -8837.034% |
| GeNeuro SA | 6.31 Million EUR | -246046.779% |
| Hyloris Pharmaceuticals SA | 47.68 Million EUR | -32489.501% |
| Innate Pharma S.A. | 184.19 Million EUR | -8336.26% |
| Inventiva S.A. | 69.13 Million EUR | -22375.014% |
| MaaT Pharma SA | 42.93 Million EUR | -36095.29% |
| MedinCell S.A. | 36.94 Million EUR | -41956.404% |
| Nanobiotix S.A. | 93.89 Million EUR | -16448.985% |
| Onward Medical N.V. | 43.62 Million EUR | -35516.219% |
| Oryzon Genomics S.A. | 106.9 Million EUR | -14435.997% |
| OSE Immunotherapeutics SA | 81.9 Million EUR | -18873.138% |
| Oxurion NV | 6.55 Million EUR | -237136.641% |
| Pharming Group N.V. | 426.33 Million EUR | -3544.747% |
| Poxel S.A. | 4.82 Million EUR | -322085.362% |
| GenSight Biologics S.A. | 9.08 Million EUR | -170902.531% |
| Transgene SA | 45.21 Million EUR | -34265.394% |
| Financière de Tubize SA | 1.92 Billion EUR | -709.22% |
| Valneva SE | 469.39 Million EUR | -3210.46% |
| Vivoryon Therapeutics N.V. | 30.82 Million EUR | -50303.841% |